Unlike cancers driven by KRAS mutations, many EGFR inhibitors have been used in the treatment for lung cancers, including Erlotinib (Tarceva), Afatinib (Gilotrif), Gefitinib (Iressa), Osimertinib (Tagrisso), Dacomitinib (Vizimpro), and Necitumumab (Portrazza). This evidence concerns the gene KRAS and cancer.